Navigation Links
InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture
Date:9/17/2009


Optiferrin shown to provide superior performance in cell culture and addresses the need for animal-free transferrin in many applications including Stem Cells, Primary Cells, Hybridoma Cells and Chinese Hamster Ovary (CHO) cells.

Fort Collins, CO September 17, 2009 / b3c newswire / C InVitria today announced the launch of Optiferrin, a high performance, well-defined and animal-free recombinant transferrin for use in mammalian cell culture. Optiferrin is a cell culture supplement which supports cell growth by regulating the amount of iron transported to the cell. Since iron is required for healthy cell culture performance, it is a critical component to reach optimal performance.

Optiferrin has undergone extensive testing by our beta customers since June 2009. They have formulated Optiferrin into their cell culture media to provide maximum performance and they liked their results. We are delighted to be able to bring this sort of value to our customers through innovations like Optiferrin, said Scott Deeter, President & CEO of InVitria.

Transferrin is natures way to deliver iron in a non-toxic manner, said Dr. Steve Pettit, InVitrias Director of Cell Culture Development. Our product development, along with beta customer results, confirmed that Optiferrin delivered optimal performance without any cell damage. This alleviates customers concerns about animal-origin infectious contaminants or the headaches caused by addition of elemental iron and iron chelators in cell culture media, said Dr. Pettit.

Optiferrin is a complimentary product to InVitrias other cell culture supplement products, which include Cellastim, Lacromin, Zap-CHO and Zap-Hybridoma.



About InVitria - www.InVitria.com
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitrias product line, contact us at info@InVitria.com or call 1-800-916-8311.


'/>"/>
b3c newswire

Related biology news :

1. InVitria Sponsors ESACT 2009 in Dublin, Ireland
2. InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO
3. InVitria Announces Launch of Recombinant Albumin for Diagnostics
4. UOG scientists successfully compete for research grants
5. McGill/JGH researchers successfully reverse multiple sclerosis in animals
6. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
7. In troubled economic times, BioSquare 2009 successfully serves as business and innovation starter
8. Salk researchers successfully reprogram keratinocytes attached to a single hair
9. Model successfully predicts large river system fish diversity
10. Scientists successfully treat new mouse model of inflammatory bowel disease
11. Researchers successfully simulate photosynthesis and design a better leaf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... have just published their findings on what they believe could be a new ... summary of the new research. Click here to read it now. ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: